Related Experiment Video
Updated: Sep 6, 2026
Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Estimation of hormone replacement therapy influence on serum galanin level in postmenopausal women
B Meczekalski1, R Słopień, A Warenik-Szymankiewicz
1Department of Gynecological Endocrinology, University of Medical Sciences in Poznań, ul. Polna 33, 60-535 Poznań, Poland.
Objective:
The aim of this study was to evaluate the influence of exogenous hormones (estradiol and progestogen) used in hormone replacement therapy (HRT) on the serum galanin level in postmenopausal women with normal body weight.
Methods:
We studied 20 postmenopausal patients (mean age 52.3 +/- 5.2 years) before and after 1 year of HRT. The mean duration of amenorrhea in these patients was 5.3 +/- 4.1 years. In all cases, body mass index was in the normal range (between 20 and 25 kg/m2). Serum galanin and estradiol concentrations were measured by radioimmunoassay before and after 1 year of treatment. Results were statistically analyzed with the use of specialist computer software.
Results:
There was no statistically significant difference in serum galanin concentration before (8.24 +/- 3.63 pg/ml) and after (5.63 +/- 2.75 pg/ml) 1 year of HRT. Following HRT the serum estradiol level (0.09 +/- 0.015 ng/ml) was significantly higher than before starting therapy (0.021 +/- 0.018 ng/ml) (p < 0.001). Also, after HRT the mean serum follicle stimulating hormone (FSH) level (32.9 +/- 28.0 IU/l) was significantly lower than before starting therapy (91.7 +/- 38.5 IU/l) (p < 0.01).
Conclusions:
The study results suggest that HRT in postmenopausal women does not restore galanin levels to values typical of those in women of reproductive age.
